DK1675846T3 - Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon - Google Patents

Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon

Info

Publication number
DK1675846T3
DK1675846T3 DK04793893.1T DK04793893T DK1675846T3 DK 1675846 T3 DK1675846 T3 DK 1675846T3 DK 04793893 T DK04793893 T DK 04793893T DK 1675846 T3 DK1675846 T3 DK 1675846T3
Authority
DK
Denmark
Prior art keywords
pyridin
trifluoromethylbenzyl
methanone
triazol
chlorophenyl
Prior art date
Application number
DK04793893.1T
Other languages
Danish (da)
English (en)
Inventor
Pamela Kaye Footman
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Shella Lenyonga Tameze
Carsten Weber
Carsten Timpe
David Scott Coffey
Alfio Borghese
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1675846T3 publication Critical patent/DK1675846T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04793893.1T 2003-10-24 2004-10-12 Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon DK1675846T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24
PCT/US2004/030914 WO2005042515A1 (en) 2003-10-24 2004-10-12 Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

Publications (1)

Publication Number Publication Date
DK1675846T3 true DK1675846T3 (da) 2010-05-31

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04793893.1T DK1675846T3 (da) 2003-10-24 2004-10-12 Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon

Country Status (28)

Country Link
US (1) US7381826B2 (https=)
JP (1) JP4959336B2 (https=)
KR (1) KR100848407B1 (https=)
CN (1) CN1863791B (https=)
AR (1) AR046131A1 (https=)
AT (1) ATE462700T1 (https=)
AU (1) AU2004285855B8 (https=)
BR (1) BRPI0415010B8 (https=)
CA (1) CA2542140C (https=)
CL (2) CL2009001310A1 (https=)
CR (1) CR8353A (https=)
DE (1) DE602004026333D1 (https=)
DK (1) DK1675846T3 (https=)
EA (1) EA008881B1 (https=)
EC (1) ECSP066517A (https=)
ES (1) ES2340772T3 (https=)
HR (1) HRP20100207T1 (https=)
IL (1) IL174926A0 (https=)
MA (1) MA28329A1 (https=)
MY (1) MY157375A (https=)
NO (1) NO335090B1 (https=)
NZ (2) NZ580480A (https=)
PE (1) PE20050481A1 (https=)
PT (1) PT1675846E (https=)
TW (1) TW200524906A (https=)
UA (1) UA82901C2 (https=)
WO (1) WO2005042515A1 (https=)
ZA (1) ZA200603234B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}·(2-氯苯基)甲酮的新中间体和方法
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체

Also Published As

Publication number Publication date
MY157375A (en) 2016-06-15
HRP20100207T1 (hr) 2010-05-31
AU2004285855B8 (en) 2011-04-28
UA82901C2 (en) 2008-05-26
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
CA2542140C (en) 2012-05-29
NO335090B1 (no) 2014-09-08
CN1863791A (zh) 2006-11-15
PT1675846E (pt) 2010-04-20
ES2340772T3 (es) 2010-06-09
JP4959336B2 (ja) 2012-06-20
EA200600829A1 (ru) 2006-08-25
NZ580480A (en) 2010-02-26
AU2004285855B2 (en) 2010-12-23
CL2009001310A1 (es) 2009-12-04
BRPI0415010B8 (pt) 2021-05-25
BRPI0415010A (pt) 2006-11-07
JP2007509143A (ja) 2007-04-12
BRPI0415010A8 (pt) 2018-05-08
CA2542140A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
ZA200603234B (en) 2007-07-25
KR20060061388A (ko) 2006-06-07
ATE462700T1 (de) 2010-04-15
PE20050481A1 (es) 2005-09-20
US20070078166A1 (en) 2007-04-05
WO2005042515A1 (en) 2005-05-12
MA28329A1 (fr) 2006-12-01
IL174926A0 (en) 2006-08-20
CL2009001311A1 (es) 2009-10-02
NZ545917A (en) 2009-11-27
AR046131A1 (es) 2005-11-23
CR8353A (es) 2006-06-06
TW200524906A (en) 2005-08-01
KR100848407B1 (ko) 2008-07-28
BRPI0415010B1 (pt) 2019-07-09
CN1863791B (zh) 2011-12-07
EA008881B1 (ru) 2007-08-31
ECSP066517A (es) 2006-10-10
AU2004285855A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
DK1675846T3 (da) Nye krystallinske former af {2-[1-(3,5-bis-trifluormethylbenzyl)-5-pyridin-4-YL-1H-[1,2,3]triazol-4-YL]-pyridin-3-YL}-(2-chlorphenyl)-methanon
IS8307A (is) Fenýl eða pýridýl amíð efnasambönd sem prostaglandín E2 mótlyf
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
IS7599A (is) Heterósýklískir kínasatálmar
DE60125980D1 (de) P38kinase-inhibitoren vom piperidin/piperazin-typ
DE60128709D1 (de) Triazol-verbindungen als protein-kinase-inhibitoren
PL2317687T3 (pl) Kontrola dostępu do szybkiego medium
IS7504A (is) Arýl keton pýrróló-tríazín efnasambönd gagnleg sem kínasatálmar
DE50313207D1 (de) Zugangskontrolle bei paketorientierten netzen
NO20052474D0 (no) Amort form av esomeprazolsalter
DE60203481D1 (de) Piperidinderivate als neurokinin 1 antagonisten
DK1505066T3 (da) Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre
NO20032315D0 (no) 4-(bifenylkarbonylamino)piperidinderivater som MTP- inhibitorer
ITMI20031080A1 (it) Apparato di controllo di una spazzola girevole,
NO20050676L (no) Krystallinsk 2,5-dion-3-(1-metyl-lH-indol-3-yl)-4-[1-(pyridin-2-ylmetyl)piperidin-4-yl]-1H-indol-3-yl]-IH-pyrrol monohydroklorid.
IS8007A (is) 4-(2-fenýlsúlfanýl-fenýl)-1,2,3,6-tetrahýdrópýridín afleiður sem serótónín endurupptöku hindrar
ATE380549T1 (de) Substituierte 1-phenethylpiperidinverbindungen, die unter anderem als analgetika verwendung finden
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
DE50308983D1 (de) Zugangskontrolle bei paketorientierten netzen
ITTO20030323A1 (it) Gruppo per l'immagazzinamento di spezzoni di lastre
HK1092475A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
CY1110642T1 (el) Νεες κρυσταλλικες μορφες {2-[1-(3,5-δις-τριφθορομεθυλ-βενζυλ)-5-πυριδιν-4-υλ-1η-[1,2,3]τριαζολ-4-υλ]- πυριδιν-3-υλ}-(2-χλωροφαινυλ)-μεθανονης
ITTO20030762A1 (it) Metodo per controllare l'istante di funzionamento di una